Innovative Product Launch Orasis Pharmaceuticals has recently launched Qlosi, a novel eye drop for presbyopia treatment, now available in the US market. This presents a prime opportunity to engage eye care professionals and clinics interested in cutting-edge presbyopia solutions.

Growing Market Focus The company's dedicated focus on presbyopia and age-related vision correction positions it to expand its customer base among ophthalmologists, optometrists, and vision care centers seeking advanced, non-invasive treatment options.

Strategic Financing Activities With recent $78M Series D funding and additional $15M structured capital secured, Orasis is investing heavily in product commercialization and market expansion, creating avenues for partnerships and sales growth within the ophthalmic pharmaceutical sector.

Leadership Expansion Key hires in quality, operations, and sales leadership strengthen Orasis's ability to scale distribution and ensure product quality, making it well-positioned to build new customer relationships and penetrate additional channels.

Growing Revenue & Market Presence Projected revenue between $25M and $50M combined with recent product launch activities offers multiple sales opportunities across healthcare providers, clinics, and pharmacy chains looking to incorporate innovative presbyopia treatments into their portfolio.